Alamar Biosciences, Inc. (ALMR) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of Alamar Biosciences, Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMR
Alamar Biosciences, Inc.
$38.13HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.78HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALMR vs RXRX
growth of $100 · dividends reinvested · last 1yALMR +73.3% (+73.3%/yr)RXRX +32.8% (+32.8%/yr)ALMR compounded faster over this window
ALMR RXRX
ALMR vs RXRX: by the numbers
- •ALMR is the larger company ($2.64B vs $2.51B market cap).
- •Both run net losses; ALMR's is the smaller (-40.18% vs -945.92% net margin).
Metrics side by side
Valuation
| Metric | ALMR | RXRX |
|---|---|---|
| P/S ratio | N/A | 45.72 |
| P/B ratio | 8.45 | 2.74 |
Profitability
| Metric | ALMR | RXRX |
|---|---|---|
| Gross margin | 56.20% | -61.96% |
| Operating margin | -42.22% | -867.87% |
| Net margin | -40.18% | -945.92% |
| ROE | N/A | -56.71% |
| ROIC | -26.95% | -49.78% |
Growth (annualized)
| Metric | ALMR | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 45.50% |
| Total return CAGR (5Y) | N/A | -25.86% |
Go deeper
Dig into the metrics
Alamar Biosciences ROERecursion Pharmaceuticals ROEAlamar Biosciences operating marginRecursion Pharmaceuticals operating marginAlamar Biosciences revenue growthRecursion Pharmaceuticals revenue growthAlamar Biosciences free cash flowRecursion Pharmaceuticals free cash flow
Alamar Biosciences & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.